Novel AI-based algorithm could improve mammogram density assessment

Researchers at the University of Eastern Finland have developed a novel artificial intelligence-based algorithm, MV-DEFEAT, to improve mammogram density assessment. This development holds promise for transforming radiological practices by enabling more precise diagnoses.

High breast tissue density is associated with an increased risk of breast cancer, and breast tissue density can be estimated from mammograms. The accurate assessment of mammograms is crucial for effective breast cancer screening, yet challenges such as variability in radiological evaluations and a global shortage of radiologists complicate these efforts. The MV-DEFEAT algorithm aims to address these issues by incorporating deep learning techniques that evaluate multiple mammogram views at the same time for mammogram density assessment, mirroring the decision-making process of radiologists.

The research team involved with AI in cancer research consists of Doctoral Researcher Gudhe Raju, Professor Arto Mannermaa and Senior Researcher Hamid Behravan. In the present study, they employed an innovative multi-view deep evidential fusion approach. Their method leverages elements of the Dempster-Shafer evidential theory and subjective logic to assess mammogram images from multiple views, thus providing a more comprehensive analysis.

MV-DEFEAT showed remarkable improvements over existing approaches. It demonstrates a significant improvement in mammogram screening accuracy by automatically and reliably quantifying the density and distribution of dense breast tissue within mammograms. For instance, in the public VinDr-Mammo dataset which consists of over 10,000 mammograms, the algorithm has achieved an impressive 50.78% improvement in distinguishing between benign and malignant tumours over the existing multi-view approach.

Interestingly, the algorithm's effectiveness persisted across different datasets, reflecting its robust performance to adapt to diverse patient demographics. The study utilised extensive data from four open-source datasets, enhancing the algorithm's applicability and accuracy across different populations. Such capabilities underline the importance of AI-based approaches in medical diagnostics. Furthermore, while MV-DEFEAT significantly aids in breast cancer screening, the team at the University of Eastern Finland emphasises the need for continued refinement and validation of the algorithm to ensure its reliability and efficacy in clinical settings.

These promising results pave the way for the use of AI in enhancing diagnostic processes, potentially leading to earlier detection and better patient outcomes in breast cancer care.

To fully integrate AI like MV-DEFEAT into clinical practice, it is crucial to build trust among healthcare professionals through rigorous testing and validation. Indeed, our next steps involve further validation studies to establish MV-DEFEAT as a reliable tool for breast cancer diagnostics in Finland."

Raju Gudhe, Doctoral Researcher of the University of Eastern Finland

Source:
Journal reference:

Gudhe, N.R., et al. (2024). A Multi-view deep evidential learning approach for mammogram density classification. IEEE Access. doi.org/10.1109/ACCESS.2024.3399204.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers question the use of "cancer" for certain prostate conditions